Literature DB >> 10969794

Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells.

V E Nava1, O Cuvillier, L C Edsall, K Kimura, S Milstien, E P Gelmann, S Spiegel.   

Abstract

Ceramide has been implicated as an important component of radiation-induced apoptosis of human prostate cancer cells. We examined the role of the sphingolipid metabolites--ceramide, sphingosine, and sphingosine-1-phosphate--in susceptibility to radiation-induced apoptosis in prostate cancer cell lines with different sensitivities to gamma-irradiation. Exposure of radiation-sensitive TSU-Pr1 cells to 8-Gy irradiation led to a sustained increase in ceramide, beginning after 12 h of treatment and increasing to 2.5- to 3-fold within 48 h. Moreover, irradiation of TSU-Pr1 cells also produced a marked and rapid 50% decrease in the activity of sphingosine kinase, the enzyme that phosphorylates sphingosine to form sphingosine-1-phosphate. In contrast, the radiation-insensitive cell line, LNCaP, had sustained sphingosine kinase activity and did not produce elevated ceramide levels on 8-Gy irradiation. Although LNCaP cells are highly resistant to gamma-irradiation-induced apoptosis, they are sensitive to the death-inducing effects of tumor necrosis factor alpha, which also increases ceramide levels in these cells (K. Kimura et al., Cancer Res., 59: 1606-1614, 1999). Moreover, we found that although irradiation alone did not increase sphingosine levels in LNCaP cells, tumor necrosis factor alpha plus irradiation induced significantly higher sphingosine levels and markedly reduced intracellular levels of sphingosine-1-phosphate. The elevation of sphingosine levels either by exogenous sphingosine or by treatment with the sphingosine kinase inhibitor N,N-dimethylsphingosine induced apoptosis and also sensitized LNCaP cells to gamma-irradiation-induced apoptosis. Our data suggest that the relative levels of sphingolipid metabolites may play a role in determining the radiosensitivity of prostate cancer cells, and that the enhancement of ceramide and sphingosine generation could be of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969794

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.

Authors:  Carolyn Loveridge; Francesca Tonelli; Tamara Leclercq; Keng Gat Lim; Jaclyn S Long; Evgeny Berdyshev; Rothwelle J Tate; Viswanathan Natarajan; Stuart M Pitson; Nigel J Pyne; Susan Pyne
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Maternal disturbance in activated sphingolipid metabolism causes pregnancy loss in mice.

Authors:  Kiyomi Mizugishi; Cuiling Li; Ana Olivera; Jacek Bielawski; Alicja Bielawska; Chu-Xia Deng; Richard L Proia
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 3.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

4.  Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Authors:  Leyre Brizuela; Claire Martin; Pauline Jeannot; Isabelle Ader; Cécile Gstalder; Guillaume Andrieu; Magalie Bocquet; Jean-Michel Laffosse; Anne Gomez-Brouchet; Bernard Malavaud; Roger A Sabbadini; Olivier Cuvillier
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

Review 5.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde.

Authors:  Noriko Takuwa; Wa Du; Erika Kaneko; Yasuo Okamoto; Kazuaki Yoshioka; Yoh Takuwa
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

Review 7.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

8.  FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

Authors:  Francesca Tonelli; Keng Gat Lim; Carolyn Loveridge; Jaclyn Long; Stuart M Pitson; Gabor Tigyi; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

Review 9.  Targeting SphK1 as a new strategy against cancer.

Authors:  Dai Shida; Kazuaki Takabe; Dmitri Kapitonov; Sheldon Milstien; Sarah Spiegel
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.